eFFECTOR Therapeutics (EFTR) Price & Analysis

Compare

264 Followers

EFTR Stock Chart & Stats

$0.02

$0.00(0.00%)

At close: Jan 07 4:00 PM EST

$0.02

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.02 - $0.02

Previous CloseN/A

Volume10.00

Average Volume (3M)79.17K

Market Cap

$2.82K

Enterprise Value$5.67M

Total Cash (Recent Filing)$25.38M

Total Debt (Recent Filing)$20.25M

Price to Earnings (P/E)―

Beta-61.71

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding4,704,409

10 Day Avg. Volume79,165

30 Day Avg. Volume79,165

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-4.41

Price to Sales (P/S)0.00

P/FCF Ratio-0.86

Enterprise Value/Market Cap2.01K

Enterprise Value/Revenue35.02

Enterprise Value/Gross Profit111.23

Enterprise Value/Ebitda-0.18

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Innovative Drug DevelopmenteFFECTOR's focus on STRIs represents a novel approach in cancer treatment, potentially offering unique therapeutic options and competitive advantages in the biotechnology sector.

Strategic PartnershipsPartnerships with larger pharmaceutical companies provide financial support and market access, enhancing eFFECTOR's ability to advance drug candidates and potentially achieve commercialization.

Industry PositioneFFECTOR's niche focus on translational control mechanisms positions it uniquely within the biotechnology industry, potentially leading to breakthroughs in cancer treatment.

Bears Say

Financial DistressThe company's financial instability, characterized by declining revenues and negative equity, raises concerns about its ability to sustain operations and invest in R&D long-term.

Negative Cash FlowPersistent negative cash flow indicates operational inefficiencies and dependency on external financing, which could hinder strategic investments and growth initiatives.

Operational InefficienciesHigh operational costs and negative margins suggest inefficiencies that could undermine profitability and competitiveness unless addressed.

eFFECTOR Therapeutics News

eFFECTOR Therapeutics Initiates Wind-Down and Leadership Change

The latest update is out from eFFECTOR Therapeutics (EFTR). eFFECTOR Therapeutics, Inc. is in the process of winding...

2y ago

EFTR

Twelve option delistings on June 24th

Option delistings effective June 24th include Pyrogenesis Canada Inc. (PYRGF), MoSys (PRSO), Nemaura Medical Inc (NMRD), LeddarTech Holdings...

2y ago

ENG

RGS

eFFECTOR to wind down operations, expects to be delisted from Nasdaq

eFFECTOR Therapeutics announced that the Company has terminated its employees and will wind down it operations, including seeking...

2y ago

EFTR

eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute

eFFECTOR Therapeutics announced a collaboration to conduct an investigator-sponsored trial evaluating zotatifin in combination with abemaciclib and letrozole...

2y ago

EFTR

eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16)

The company had cash, cash equivalents, and short-term investments totaling $25.4M as of March 31 compared to $18.4M...

2y ago

EFTR

eFFECTOR Therapeutics trading resumes

09:00 EDT eFFECTOR Therapeutics trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

2y ago

EFTR

eFfector sees no ‘obvious’ path forward for tomivosertib development in NSCLC

eFFECTOR Therapeutics announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested...

2y ago

EFTR

eFFECTOR Therapeutics trading halted, news pending

08:25 EDT eFFECTOR Therapeutics trading halted, news pending Published first on TheFly – the ultimate source for real-time,...

2y ago

EFTR

Effector Therapeutics’ Stock Issuance Capped: Navigating the Lincoln Park Agreement’s Exchange Limit

Effector Therapeutics, Inc. (EFTR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Effector...

2y ago

EFTR

eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)

Revenue was zero for the quarter ended December 31 compared to approximately $0.7M for the same quarter of...

2y ago

EFTR

EFTR Earnings this Week: How Will it Perform?

Effector Therapeutics, Inc. (EFTR) is scheduled to report 4th quarter earnings on 03/13/2024. Regarding Q4 estimates, Wall Street...

2y ago

EFTR

eFfector Therapeutics target adjusted to $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on eFfector Therapeutics to $24 from $5 and keeps a Buy...

2y ago

EFTR

eFFECTOR Therapeutics Regains Nasdaq Compliance Status

eFFECTOR Therapeutics (EFTR) has released an update. eFFECTOR Therapeutics, Inc. has received confirmation from Nasdaq that it has...

2y ago

EFTR

eFFECTOR Therapeutics Secures $15M in Direct Offering

eFFECTOR Therapeutics (EFTR) has released an update to notify the public and investors about an entry into a...

2y ago

EFTR

EFTR FAQ

What was eFFECTOR Therapeutics’s price range in the past 12 months?

eFFECTOR Therapeutics lowest stock price was $0.02 and its highest was $0.02 in the past 12 months.

What is eFFECTOR Therapeutics’s market cap?

eFFECTOR Therapeutics’s market cap is $2.82K.

When is eFFECTOR Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were eFFECTOR Therapeutics’s earnings last quarter?

Currently, no data Available

Is eFFECTOR Therapeutics overvalued?

According to Wall Street analysts eFFECTOR Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does eFFECTOR Therapeutics pay dividends?

eFFECTOR Therapeutics does not currently pay dividends.

What is eFFECTOR Therapeutics’s EPS estimate?

eFFECTOR Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does eFFECTOR Therapeutics have?

eFFECTOR Therapeutics has 4,704,409 shares outstanding.

What happened to eFFECTOR Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of eFFECTOR Therapeutics?

Currently, no hedge funds are holding shares in EFTR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.